Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Wednesday 18 September, 2019

Irish Takeover Panel

Disclosure Table

RNS Number : 8575M
Irish Takeover Panel
18 September 2019
 

IRISH TAKEOVER PANEL
Disclosure Table

The following companies are deemed to be in an offer period for the purposes of disclosure under the Rules of the Irish Takeover Panel:

___________________________________________________________

 

 

Offeree:         Green REIT plc

 

Offer period commenced:    15 April 2019

 

€0.10 ordinary shares,  ISIN: IE00BBR67J55,  NSI: 699,469,638

 

Offeror:         HPREF Dublin Office Bidco Limited, an indirect wholly-owned    

                      subsidiary of the Henderson Park Funds

 

Disclosure of interests and dealings in the relevant securities of the above offeror is not required.

 

___________________________________________________________

 

Offeree:         SCISYS Group Plc

Offer period commenced: 14 June 2019

£0.25 ordinary shares; ISIN: IE00BD9PKV79; NSI:29,608,160

Offeror:          CGI Group Holdings Europe Limited a wholly-owned indirect                                      subsidiary of         CGI INC

___________________________________________________________

 

Offeree:         Allergan plc

Offer period commenced: 25 June 2019

US$0.0001 ordinary shares ; ISIN: IE00BY9D5467; NSI:327,823,903

Offeror:          AbbVie Inc.

US$0.01 common stock; ISIN: US00287Y1091; NSI: 1,478,779,037                       

 

___________________________________________________________

 

 

 

Irish Takeover Panel                                     18 September 2019

Lower Ground Floor

76 Merrion Square

Dublin D02 NY76

 

Telephone:     + 353-1-678 9020                            


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEMMGMLKRFGLZM

a d v e r t i s e m e n t